- Home
- CDTX vs CELC Comparison
CDTX vs CELC Comparison
Compare CDTX & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTX
- CELC
- Stock Information
- Founded
- CDTX 2012
- CELC 2011
- Country
- CDTX United States
- CELC United States
- Employees
- CDTX N/A
- CELC N/A
- Industry
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- CELC Medical Specialities
- Sector
- CDTX Health Care
- CELC Health Care
- Exchange
- CDTX Nasdaq
- CELC Nasdaq
- Market Cap
- CDTX 333.3M
- CELC 327.3M
- IPO Year
- CDTX 2015
- CELC 2017
- Fundamental
- Price
- CDTX $21.68
- CELC $10.63
- Analyst Decision
- CDTX Strong Buy
- CELC Strong Buy
- Analyst Count
- CDTX 8
- CELC 5
- Target Price
- CDTX $41.17
- CELC $30.80
- AVG Volume (30 Days)
- CDTX 157.5K
- CELC 152.9K
- Earning Date
- CDTX 05-08-2025
- CELC 05-14-2025
- Dividend Yield
- CDTX N/A
- CELC N/A
- EPS Growth
- CDTX N/A
- CELC N/A
- EPS
- CDTX N/A
- CELC N/A
- Revenue
- CDTX $302,000.00
- CELC N/A
- Revenue This Year
- CDTX N/A
- CELC N/A
- Revenue Next Year
- CDTX N/A
- CELC N/A
- P/E Ratio
- CDTX N/A
- CELC N/A
- Revenue Growth
- CDTX N/A
- CELC N/A
- 52 Week Low
- CDTX $10.14
- CELC $7.58
- 52 Week High
- CDTX $28.42
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- CDTX 47.21
- CELC 51.32
- Support Level
- CDTX $18.91
- CELC $10.26
- Resistance Level
- CDTX $24.91
- CELC $10.88
- Average True Range (ATR)
- CDTX 1.86
- CELC 0.59
- MACD
- CDTX -0.18
- CELC -0.02
- Stochastic Oscillator
- CDTX 33.41
- CELC 58.33
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.